38
Participants
Start Date
June 10, 2020
Primary Completion Date
February 29, 2024
Study Completion Date
September 12, 2025
Guselkumab
Guselkumab will be administered intravenously for the first 3 doses and then subcutaneously for the subsequent doses.
Kishiwada Tokushukai Hospital, Kishiwada
Toyama Prefectural Central Hospital, Toyama
Sendai Kosei Hospital, Sendai Miyagi
KOKIKAI Tokatsu Tsujinaka Hospital, Abiko
Institute of Science Tokyo Hospital, Bunkyō City
Hitachi General Hospital, Hitachi
Asahikawa Medical University Hospital, Hokkaido
Ofuna Chuo Hospital, Kamakura
Kumamoto University Hospital, Kumamoto
Japanese Red Cross Kumamoto Hospital, Kumamoto
Kyorin University Hospital, Mitaka
Kenseikai Dongo Hospital, Nara
Hyogo Medical University Hospital, Nishinomiya Shi
Okayama University Hospital, Okayama
Ishida Clinic of IBD and Gastroenterology, Ōita
Saga University Hospital, Saga
Kitasato University Hospital, Sagamihara
Saitama Medical Center, Saitama
Sapporo Tokushukai Hospital, Sapporo
Jichi Medical University Hospital, Shimotsuke
National Center for Global Health and Medicine, Shinjuku
Tokyo Women's Medical University Hospital, Shinjuku-ku
Tokyo Metropolitan Bokutoh Hospital, Sumida Ku
Osaka Medical and Pharmaceutical University Hospital, Takatsuki
National Hospital Organization Toyohashi Medical Center, Toyohashi
Lead Sponsor
Janssen Pharmaceutical K.K.
INDUSTRY